Showing results (91-100 of 185) with videos related to
Sort By:
Pageof 19
Haematologica|February 1, 2024
Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysisPaul G Richardson, Aurore Perrot, Jesus San Miguel, et al.The Lancet. Oncology|February 13, 2022
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 studyPaul G Richardson, Aurore Perrot, Jesus San-Miguel, et al.British Journal of Haematology|December 23, 2016
Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myelomaNoopur S Raje, Philippe Moreau, Evangelos Terpos, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2022
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III TrialPieter Sonneveld, Asher Chanan-Khan, Katja Weisel, et al.The Lancet. Haematology|October 4, 2023
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trialMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.Blood|March 14, 2013
Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 studyGösta Gahrton, Simona Iacobelli, Bo Björkstrand, et al.Blood|December 9, 2024
Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUSOla Landgren, Ajai Chari, Yael C Cohen, et al.Hemasphere|January 12, 2026
Daratumumab-based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 studyMeral Beksac, Tulin Fıratlı Tuglular, Francesca Gay, et al.British Journal of Haematology|April 7, 2017
Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II studyOrhan Sezer, Meral Beksac, Roman Hajek, et al.The New England Journal of Medicine|June 3, 2024
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple MyelomaMeletios Athanasios Dimopoulos, Meral Beksac, Ludek Pour, et al.Pageof 19